alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 58.35 Quality assurance unit. ( a ) A testing facility shall have a quality assurance unit which shall be responsible for monitoring each study to assure management that the facilities, equipment, personnel, methods, practices, records, and controls are in conformance with the regulations in this part. For any given study, the quality assurance unit shall be entirely separate from and independent of the personnel engaged in the direction and conduct of that study.
( b ) The quality assurance unit shall: ( 1 ) Maintain a copy of a master schedule sheet of all nonclinical laboratory studies conducted at the testing facility indexed by test article and containing the test system, nature of study, date study was initiated, current status of each study, identity of the sponsor, and name of the study director.
( 2 ) Maintain copies of all protocols pertaining to all nonclinical laboratory studies for which the unit is responsible.
( 3 ) Inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection showing the date of the inspection, the study inspected, the phase or segment of the study inspected, the person performing the inspection, findings and problems, action recommended and taken to resolve existing problems, and any scheduled date for reinspection. Any problems found during the course of an inspection which are likely to affect study integrity shall be brought to the attention of the study director and management immediately.
( 4 ) Periodically submit to management and the study director written status reports on each study, noting any problems and the corrective actions taken.
( 5 ) Determine that no deviations from approved protocols or standard operating procedures were made without proper authorization and documentation.
( 6 ) Review the final study report to assure that such report accurately describes the methods and standard operating procedures, and that the reported results accurately reflect the raw data of the nonclinical laboratory study.
( 7 ) Prepare and sign a statement to be included with the final study report which shall specify the dates inspections were made and findings reported to management and to the study director.
( c ) The responsibilities and procedures applicable to the quality assurance unit, the records maintained by the quality assurance unit, and the method of indexing such records shall be in writing and shall be maintained. These items including inspection dates, the study inspected, the phase or segment of the study inspected, and the name of the individual performing the inspection shall be made available for inspection to authorized employees of the Food and Drug Administration.
( d ) A designated representative of the Food and Drug Administration shall have access to the written procedures established for the inspection and may request testing facility management to certify that inspections are being implemented, performed, documented, and followed-up in accordance with this paragraph.
[43 FR 60013, Dec. 22, 1978, as amended at 52 FR 33780, Sept. 4, 1987; 67 FR 9585, Mar. 4, 2002]
<PAGE>   1
 
                                                                    EXHIBIT 11.1
 
                                  MINIMED INC.
 
            STATEMENT OF COMPUTATION OF NET INCOME (LOSS) PER SHARE
 
<TABLE>
<CAPTION>
                                                         YEAR ENDED       YEAR ENDED       YEAR ENDED
                                                        DECEMBER 31,     DECEMBER 29,     DECEMBER 27,
                                                        ------------     ------------     ------------
                                                            1994             1995             1996
                                                        ------------     ------------     ------------
<S>                                                     <C>              <C>              <C>
Weighted average common shares outstanding............    7,768,000        9,293,000       11,566,000
Common equivalent shares from stock options and
  warrants............................................      206,000          646,000          672,000
Redeemable convertible preferred stock................    1,111,000          648,000
                                                          ---------       ----------       ----------
Shares used in per share calculation..................    9,085,000       10,587,000       12,238,000
                                                          =========       ==========       ==========
Net income (loss).....................................   $ (900,000)      $1,809,000       $4,672,000
                                                          =========       ==========       ==========
Net income (loss) per share...........................        $(.10)            $.17             $.38
                                                          =========       ==========       ==========
</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GLAMIS GOLD
LTD. CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 1999
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10Q
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                          31,707
<SECURITIES>                                         0
<RECEIVABLES>                                    4,553
<ALLOWANCES>                                         0
<INVENTORY>                                     16,340
<CURRENT-ASSETS>                                53,261
<PP&E>                                         331,229
<DEPRECIATION>                                 207,099
<TOTAL-ASSETS>                                 185,977
<CURRENT-LIABILITIES>                           15,844
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       157,292
<OTHER-SE>                                     (5,134)
<TOTAL-LIABILITY-AND-EQUITY>                   185,977
<SALES>                                         22,744
<TOTAL-REVENUES>                                22,744
<CGS>                                           20,712
<TOTAL-COSTS>                                   30,636
<OTHER-EXPENSES>                               (1,647)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 170
<INCOME-PRETAX>                                (6,415)
<INCOME-TAX>                                     (412)
<INCOME-CONTINUING>                            (6,003)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (6,003)
<EPS-BASIC>                                     (0.10)
<EPS-DILUTED>                                   (0.10)


</TABLE>
§ 556.310 Haloxon. ( a ) [Reserved]
( b ) *Tolerances.* The tolerance for haloxon is: ( 1 ) *Cattle.* Edible tissues (excluding milk): 0.1 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 520.1120a and 520.1120b of this chapter.
§ 640.11 General requirements. ( a ) *Storage.* Immediately after processing, the Red Blood Cells shall be placed in storage and maintained at a temperature between 1 and 6 °C.
( b ) *Inspection.* The product shall be inspected immediately after separation of the plasma, periodically during storage, and at the time of issue. The product shall not be issued if there is any abnormality in color or physical appearance or if there is any indication of microbial contamination.
[38 FR 32089, Nov. 20, 1973, as amended at 41 FR 18292, May 3, 1976; 42 FR 59878, Nov. 11, 1977; 50 FR 4139, Jan. 29, 1985]
. . . . 

‘. OFFICE OF THE A’ITORNEY GENERAL OF TEXAS 

AUSTIN
§ 556.748 Tylvalosin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residues of tylvalosin is 47.7 μg/kg of body weight per day.
( b ) *Tolerances.* A tolerance for tylvalosin in edible tissues of swine is not required.
( c ) *Related conditions of use.* See §§ 520.2645 and 558.633 of this chapter.
EXHIBIT 31.1

                     Rule 13a-14(a)/15d-14(a) Certification

I, Peter P. Phildius, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Avitar, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact  necessary to make the statements
made, in light of the  circumstances  under which such statements were made, not
misleading with respect to the period covered by this report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information included in this report, fairly present in all material respects the
financial  condition,  results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The  registrant's  other  certifying  officer(s)  and I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

     a)  Designed  such  disclosure  controls  and  procedures,  or caused  such
disclosure  controls and  procedures to be designed  under our  supervision,  to
ensure that  material  information  relating to the  registrant,  including  its
consolidated subsidiaries,  is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

     b) Evaluated the effectiveness of the registrant's  disclosure controls and
procedures and presented in this report our conclusions  about the effectiveness
of the disclosure controls and procedures as of the end of the period covered by
this report based on such evaluation; and

     c) Disclosed in this report any change in the registrant's internal control
over  financial  reporting  that occurred  during the  registrant's  most recent
fiscal quarter (the registrant's  fourth fiscal quarter in the case of an annual
report) that has  materially  affected,  or is  reasonably  likely to materially
affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying  officer(s) and I have disclosed,  based on
our most recent evaluation of the internal control over financial reporting,  to
the registrant's  auditors and the audit committee of the registrant's  board of
directors (or persons performing the equivalent functions):

     a) All significant  deficiencies  and material  weaknesses in the design or
operation of internal  controls over  financial  reporting  which are reasonably
likely  to  adversely  affect  the  registrant's  ability  to  record,  process,
summarize and report financial information; and

     b) Any fraud,  whether or not material,  that involves  management or other
employees who have a significant role in the registrant's  internal control over
financial reporting.


Date:  May 15, 2006                    /S/ Peter P. Phildius
                                       Peter P. Phildius
                                       Chairman and Chief
                                       Executive Officer
                                       (Principal Executive Officer)
# C_2015155EN.01002701.xml

| 11.5.2015 | EN | Official Journal of the European Union | C 155/27 |
| --- | --- | --- | --- |

11.5.2015

EN

Official Journal of the European Union

C 155/27

---

Judgment of the General Court of 26 March 2015 — Bateaux mouches v OHIM (BATEAUX MOUCHES)

(Case T-72/14) (1)

1

((Community trade mark - International registration designating the European Community - Word mark BATEAUX MOUCHES - Absolute ground for refusal - No distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009 - No distinctive character acquired through use - Article 7(3) of Regulation No 207/2009))

(2015/C 155/31)

Language of the case: French

Parties

Parties

Applicant: Compagnie des bateaux mouches SA (Paris, France) (represented by: G. Barbaut, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: V. Melgar, Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 15 November 2013 (Case R 284/2013-2) concerning the registration of the word mark BATEAUX MOUCHES as an international registration designating the European Community.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Compagnie des bateaux mouches SA to pay the costs. |
| --- | --- |

2.

Orders Compagnie des bateaux mouches SA to pay the costs.

---

(1)  OJ C 102, 7.4.2014.

1

---
**Exhibit 31.2**
**Certifications**
I, Thomas J. Koenig, certify that:
1.  I have reviewed this annual report on Form 10-K of Day International Group, Inc.; 2.  Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report; 3.  Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in thisreport; 4.  The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relatingto the registrant, including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this report is being prepared;
b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and
c) Disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’sfourth fiscal quarter in the case of an annual report) that has materially affected, or isreasonably likely to materially affect, the registrant’s internal control over financialreporting; and
5.  The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performing the equivalentfunctions):
a) All significant deficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.     Date: March 24, 2005 By: /s/ Thomas J. Koenig      Thomas J. Koenig  Vice President and Chief Financial  Officer (Principal Financial Officer and  Principal Accounting Officer)
Scott W. Anderson
Vice President/Residential Assets

OCWEN
(LOGO)

July 19, 1999

Telephone 561-682-8913
Facsimile 561-682-8186

Norwest Bank Minnesota, National Associate
Diane Tenhoopen
11000 Broken Land Parkway
Columbia, Maryland 21044

RE:

         Officer  Certification  Ocwen 1997-OFS3 Ocwen 1998-OFS1 Ocwen 1998-OFS2
         Ocwen 1998-OFS3 Ocwen 1998-OFS4  Equicon 94-1 Equicon 94-2 Equicon 95-1
         Equicon 95-2 Access 96-1 Access 96-2 Access 96-3

Dear Ms. Tenhoopen:

Pursuant to the applicable sections of the above Servicing  Agreements,  I Scott
W.  Anderson as officer of Ocwen  Federal Bank FSB (the  "Bank")  confirm that a
review of the  activities of the Bank ended December 31, 1998 and of performance
under the Servicing  Agreements has been made under my supervision.  To the best
of my  knowledge,  based  on such  review,  the Bank  has  fulfilled  all of its
obligations under the Servicing Agreement  throughout the period,  other than as
noted in the Management Assertion on Compliance with USAP.

Sincerely,

Scott W. Anderson
Vice President Residential Assets

SWA/dls

The Forum 1675 Palm Beach Lakes Boulevard, West Palm Beach. FL 33401
§ 640.50 Cryoprecipitated AHF. ( a ) *Proper name and definition.* The proper name of this product shall be Cryoprecipitated AHF. The product is defined as a preparation of antihemophilic factor, which is obtained from a single unit of plasma collected and processed in a closed system.
( b ) *Source.* The source material for Cryoprecipitated AHF shall be plasma which may be obtained by whole blood collection or by plasmapheresis.
[42 FR 21774, Apr. 29, 1977; 48 FR 13026, Mar. 29, 1983, as amended at 50 FR 4139, Jan. 29, 1985]
[Cite as Parsons v. Ohio Dept. of Transp. , 2011-Ohio-5985.]



# Court of Claims of Ohio

The Ohio Judicial Center 65 South Front Street, Third Floor Columbus, OH 43215
614.387.9800 or 1.800.824.8263
www.cco.state.oh.us

MARK E. PARSONS, Case No. 2008-11290

Plaintiff,

v. Judge Joseph T. Clark

OHIO DEPARTMENT OF TRANSPORTATION,

Defendant. JUDGMENT ENTRY

{¶1} On September 14, 2011, the magistrate issued a decision recommending

judgment for defendant.

{¶2} Civ.R. 53(D)(3)(b)(i) states, in part: “A party may file written objections to a

magistrate’s decision within fourteen days of t he filing of the decision, whether or not the

court has adopted the decision during that fourteen-day period as permitted by Civ.R.

53(D)(4)(e)(i).” No objections were filed.

{¶3} The court determines that there is no error of law or other defect evident on

the face of the magistrate’s decision. Therefore, the court adopts the magistrate’s

decision and recommendation as its own, including findings of fact and conclusions of

law contained therein. Judgment is rendered in favor of defendant. Court costs are

assessed against plaintiff. The clerk shall serve upon all parties notice of this judgment

and its date of entry upon the journal.

_____________________________________ JOSEPH T. CLARK Judge

cc:

Christopher P. Conomy
A ssistant Attorney General 150 East Gay Street, 18th Floor Columbus, Ohio 43215-3130 Mark E. Parsons 14653 State Route 555 Cutler, Ohio 45724Case No. 2008-11290 - 2 - JUDGMENT ENTRY

Filed October 18, 2011 To S.C. reporter November 18, 2011
# C_2014431EN.01004801.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/48 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/48

---

Action brought on 24 June 2014 — ZZ v European Commission

(Case F-59/14)

(2014/C 431/76)

Language of the case: German

Parties

Parties

Applicant: ZZ (represented by: H. Mannes, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Civil service — Application for compensation for the material and non-pecuniary loss, together with default interest, which the applicant has suffered by means of loss of an opportunity to obtain a post with the EU, based on the judgment of the Civil Service Tribunal of 29 September 2010 in Case F-5/08 Brune v Commission.

Brune

Commission

Form of order sought

Form of order sought

The applicant claims that the Civil Service Tribunal should:

| — | Order the defendant to pay compensation to the applicant for the material and non-pecuniary loss, together with default interest, which the latter has suffered as a result of his unlawful exclusion from open competition EPSO/AD/26/05; |
| --- | --- |

—

Order the defendant to pay compensation to the applicant for the material and non-pecuniary loss, together with default interest, which the latter has suffered as a result of his unlawful exclusion from open competition EPSO/AD/26/05;

| — | Order the defendant to pay the costs of the proceedings; |
| --- | --- |

—

Order the defendant to pay the costs of the proceedings;

| — | As a precaution, give judgment in default. |
| --- | --- |

—

As a precaution, give judgment in default.

---
##### 



EXHIBIT 99(b)

CERTIFICATION PURSUANT TO 18 U.S.CSECTION 1350, AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002

In connection with the Quarterly Report of Northland Cable Properties Seven
Limited Partnership (the Partnership) on Form 10Q for the period ended
September 30, 2002 as filed with the Securities and Exchange Commission on the
date hereof (the Form 10-Q), I, Gary Jones, President of Northland
Communications Corporation, the General Partner, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that;



| | (1) |  | The Form 10-Q fully complies with the requirements of
Section 13 (a) or (15(d) of the Securities Exchange Act of 1934
(15 U.S.C. 78m or 78(d)); and       
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Form 10-Q fairly
presents in all material respects, the financial condition and
results of operations of the Partnership.



Dated: November 12, 2002

| |  |     |  |                                                                                        
| |  | --- |  | ---------------------------------------------------------------------------------------
|
|
|
| |  | BY: |  | /s/  GARY S. JONES
Gary S. Jones
President
(Principal Financial and Accounting Officer)
§ 524.1204 Kanamycin, amphomycin, and hydrocortisone ointment. ( a ) *Specifications.* Each gram of ointment contains 5 milligrams kanamycin activity as kanamycin sulfate, 5 milligrams of amphomycin activity as the calcium salt, and 10 milligrams of hydrocortisone acetate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Apply to the affected areas of the skin at least twice daily. In severe or widespread lesions it may be desirable to apply the ointment more than twice daily. After some improvement is observed, treatment can usually be reduced to once daily.
( 2 ) *Indications for use.* For the treatment of acute otitis externa, furunculosis, folliculitis, pruritus, anal gland infections, erythema, decubital ulcers, superficial wounds, and superficial abscesses associated with bacterial infections caused by organisms susceptible to one or both antibiotics.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 10970, Feb. 27, 2014]